Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
amyotrophic lateral sclerosis
Biotech
Another biotech hit with FDA delay for ALS asset
Neurizon's postponement follows Coya Therapeutics' similar delay for an ALS asset's IND application.
Darren Incorvaia
Aug 18, 2025 11:01am
Synchron links BCI device to iPad through new Apple protocol
Aug 4, 2025 11:30am
FDA delays hit clinical trial launch decisions
Jul 30, 2025 10:29am
Corcept unveils promising survival data from phase 2 ALS fail
Jun 5, 2025 8:21am
Ferrer nabs European rights for ALS asset in €500M pact
Apr 28, 2025 2:40pm
Denali’s ALS drug comes up short in trial extension
Mar 6, 2025 8:20am
